Related Experiment Video
Updated: Jul 26, 2026
07:37
Roux-en-Y Gastric Bypass Operation in Rats
Published on: June 11, 2012
Effect of adrenergic agents on postgastrectomy hypoglycemia
Diabetes
|November 1, 1975
Summary
Reactive hypoglycemia in postgastrectomy patients can be managed with propranolol. This beta-blocker effectively raised blood glucose levels and prevented hypoglycemia symptoms, unlike phenylephrine.
Area of Science:
- Endocrinology
- Gastroenterology
- Pharmacology
Background:
- Postgastrectomy patients are susceptible to reactive hypoglycemia.
- Symptoms include nausea, flushing, fatigue, and neuroglycopenic/adrenergic events.
Purpose of the Study:
- To evaluate the efficacy of phenylephrine and propranolol in managing reactive hypoglycemia postgastrectomy.
- To assess the impact of these drugs on glucose levels and hypoglycemia symptoms.
Main Methods:
- Ten postgastrectomy patients underwent oral glucose tolerance tests (OGTT).
- Medications (phenylephrine or propranolol) were administered before repeat OGTTs.
- Plasma glucose, insulin levels, and glucose utilization rates were measured.
Main Results:
- Phenylephrine slightly raised lowest plasma glucose but did not prevent symptoms.
- Propranolol significantly raised lowest plasma glucose and prevented early and late hypoglycemia symptoms.
- Neither drug affected peak or total plasma insulin levels or glucose utilization rates.
Conclusions:
- Propranolol effectively ameliorated symptoms and chemical hypoglycemia after oral glucose in postgastrectomy patients.
- Propranolol warrants further investigation as a potential long-term therapy for this condition.
Related Concept Videos
01:26Oral Hypoglycemic Agents: Biguanides and Glitazones
Biguanides, particularly metformin (Glucophage), are insulin sensitizers that enhance glucose uptake, thereby reducing insulin resistance. Unlike sulfonylureas, metformin doesn't prompt insulin secretion, which helps to curb hypoglycemia risk. Metformin is beneficial in treating conditions like polycystic ovary syndrome due to its insulin-resistance reduction capability. The drug's primary action involves curtailing hepatic gluconeogenesis, a significant contributor to high blood glucose levels...
01:06Oral Hypoglycemic Agents: Glinides
Repaglinide (Prandin) and Nateglinide (Starlix), known as glinides, are oral insulin secretagogues that stimulate insulin release from pancreatic β cells by closing the ATP-sensitive potassium channels (KATP channel). Repaglinide controls insulin release from pancreatic β cells by managing potassium efflux. It shares two binding sites with sulfonylureas and also has a unique site, indicating overlapping mechanisms of action. With a rapid onset and a 4-7 hour duration, it effectively manages...
01:19Oral Hypoglycemic Agents: α-Glucosidase Inhibitors
α-glucosidase inhibitors, including acarbose (Precose), miglitol (Glyset), and voglibose (Voglib) (primarily available in Asia), are drugs that control blood sugar levels by delaying the digestion of starch and disaccharides. They achieve this by inhibiting α-glucosidase enzymes in the intestine, which slow the absorption of carbohydrates in the intestine, which in turn leads to a prolonged release of the glucoregulatory hormone GLP-1 from intestinal L-cells.
Acarbose and miglitol are typically...
Acarbose and miglitol are typically...
01:24Glucagon-like Receptor Agonists
Incretins include glucagon-like peptide-1 (GLP-1) and glucose-dependent insulinotropic polypeptide (GIP), which stimulate insulin secretion post-meals. In type 2 diabetes, GIP's efficacy is reduced, making GLP-1 a viable drug target. GIP originates from preproGIP.
GLP-1, when administered in high doses intravenously, triggers insulin secretion, inhibits glucagon release, slows gastric emptying, reduces food intake, and restores normal insulin secretion. However, its rapid inactivation by the...
GLP-1, when administered in high doses intravenously, triggers insulin secretion, inhibits glucagon release, slows gastric emptying, reduces food intake, and restores normal insulin secretion. However, its rapid inactivation by the...
01:15Hypoglycemia and Glucagon
Without prolonged fasting, healthy individuals maintain blood glucose levels above 3.5 mM due to a well-adapted neuroendocrine counterregulatory system that effectively prevents acute hypoglycemia, a potentially life-threatening condition. The primary clinical scenarios for hypoglycemia encompass diabetes treatment, inappropriate production of endogenous insulin or insulin-like substances by tumors, and the use of glucose-lowering agents in non-diabetic individuals. Notably, hypoglycemia in the...
01:26Hypoglycemia
Hypoglycemia is a blood glucose level below 70 mg/dL. It commonly occurs in individuals using insulin or insulin-secreting drugs, but may also arise in non-diabetic conditions. People with type 1 diabetes are at the highest risk because they depend on exogenous insulin. People with type 2 diabetes are also at risk, especially when treated with insulin or medications such as sulfonylureas, which increase insulin release regardless of blood glucose levels. It develops when insulin levels exceed...